DGAP-News

Press Release: 4SC's partner Yakult Honsha completes Phase I part of clinical study with resminostat in Asian HCC patients and starts randomised Phase II part - Seite 4

up to EUR127 million payable upon achieving specified milestones including
clinical and regulatory events in Japan. In addition to milestone payments,
Yakult will pay 4SC double-digit royalties linked to product sales of
resminostat. Yakult Honsha will be responsible for all clinical
requirements for resminostat development in Japan in oncology indications.
4SC is aiming to partner this compound in other territories, including
Europe, the USA and Asia.

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a
headcount of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed
on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: [phone]

MC Services
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: [phone]

The Trout Group
Chad Rubin
crubin(at)troutgroup.com, Tel.: [phone]




---------------------------------------------------------------------

23.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
288033 23.09.2014